Safety of convalescent plasma therapy for COVID-19 patients and analysis of viral kinetics: a single-center, open-label, single-arm, interventional study in Japan-Reference-Cited by-同舟云学术

Safety of convalescent plasma therapy for COVID-19 patients and analysis of viral kinetics: a single-center, open-label, single-arm, interventional study in Japan

Published:2022-08-05 Issue:1 Volume:2 Page:38-43
ISSN:2436-293X
Container-title:GHM Open
language:en
Short-container-title:GHM Open

Author:

Kutsuna Satoshi¹,Saito Sho¹,Takamatsu Yuki²,Terada Mari¹,Togano Tomiteru³,Kinoshita Noriko¹,Maeda Kenji²,Matsunaga Akihiro⁴,Satake Masahiro⁵,Matsubayashi Keiji⁵,Tsuno Nelson Hirokazu⁶,Kojima Makiko⁵,Kuramitsu Madoka⁷,Tezuka Kenta⁷,Ikebe Emi⁷,Okuma Kazu⁷,Hamaguchi Isao⁷,Shimanishi Yumiko¹,Hangaishi Akira³,Ishizaka Yukihito⁴,Ohmagari Norio¹,Mitsuya Hiroaki²

Affiliation:

1. Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

2. Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.

3. Department of Hematology, National Center for Global Health and Medicine, Tokyo, Japan.

4. Department of Intractable Diseases, National Center for Global Health and Medicine, Tokyo, Japan.

5. Japanese Red Cross Central Blood Institute, Tokyo, Japan.

6. Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.

7. Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo, Japan.

Publisher

National Center for Global Health and Medicine (JST)

Link

https://www.jstage.jst.go.jp/article/ghmo/2/1/2_2022.01002/_pdf

Reference29 articles.

1. 1. World Health Organization. Weekly epidemiological update - 30 November 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---30-november-2021 (accessed February 9, 2022).

2. 2. Kutsuna S. Coronavirus disease 2019 (COVID-19): research progress and clinical practice. Glob Health Med. 2020; 2:78-88.

3. 3. Martinot M, Jary A, Fafi-Kremer S, Leducq V, Delagreverie H, Garnier M, Pacanowski J, Mékinian A, Pirenne F, Tiberghien P, Calvez V, Humbrecht C, Marcelin AG, Lacombe K. Emerging RNA-dependent RNA polymerase mutation in a remdesivir-treated B-cell immunodeficient patient with protracted coronavirus disease 2019. Clin Infect Dis. 2021; 5;73:e1762-e1765.

4. 4. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006; 17;145:599-609.

5. 5. Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet. 1979; 2:1216-1217.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals;Life;2023-11-09

2. Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial;Journal of Infection and Chemotherapy;2023-09

3. Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review;Journal of Blood Medicine;2023-02

4. Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma;Transfusion and Apheresis Science;2022-12